166 related articles for article (PubMed ID: 2202770)
1. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770
[TBL] [Abstract][Full Text] [Related]
2. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311
[TBL] [Abstract][Full Text] [Related]
3. [Oral administration of OK-432 (picibanil). (8th report) clinical application: its immunomodulatory effects on the patients with gastrointestinal cancers].
Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1607-15. PubMed ID: 2809385
[TBL] [Abstract][Full Text] [Related]
4. [Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer].
Nio Y; Tobe T
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1436-8. PubMed ID: 2586435
[TBL] [Abstract][Full Text] [Related]
5. Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer.
Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tobe T
Biotherapy; 1990; 2(3):213-22. PubMed ID: 2206774
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of immunological response of regional lymph node lymphocytes from patients with gastric cancer after endoscopic local injection of biological response modifier (BRM)].
Obi Y
Nihon Geka Gakkai Zasshi; 1991 Mar; 92(3):293-302. PubMed ID: 2051981
[TBL] [Abstract][Full Text] [Related]
7. [Augmentation of cytotoxicity of regional lymph node lymphocytes of gastric cancer after intratumoral injection of OK-432].
Kobayashi G
Nihon Geka Gakkai Zasshi; 1990 Jan; 91(1):68-76. PubMed ID: 2314383
[TBL] [Abstract][Full Text] [Related]
8. [Endoscopic preoperative intralesional injection of OK-432 in early gastric cancer].
Yamane T; Sagara Y; Suzuki G; Kasuga M; Sakita M; Fujita Y; Majima S
Gan To Kagaku Ryoho; 1984 Apr; 11(4):930-4. PubMed ID: 6721507
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of gastric cancer].
Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771
[TBL] [Abstract][Full Text] [Related]
10. [Clinical trial of oral immunotherapy with streptococcal preparation OK 432 on gastric cancer].
Nio Y; Ohgaki K; Henmi K; Kan N; Inamoto T; Tsuchitani T; Kodama H; Tobe T
Nihon Gan Chiryo Gakkai Shi; 1982 Apr; 17(3):728-34. PubMed ID: 6752308
[No Abstract] [Full Text] [Related]
11. Effect of OK-432 on cytotoxic activity in cancer patients without tumor burden.
Fujieda S; Saito H; Isobe Y; Nakagawara G; Nishi O; Nagahara K; Watanabe Y; Hoshino T
Anticancer Res; 1992; 12(6B):1941-5. PubMed ID: 1341892
[TBL] [Abstract][Full Text] [Related]
12. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation.
Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T
Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432
[TBL] [Abstract][Full Text] [Related]
13. [Preoperative immunotherapy in patients with gastric cancer--with special reference to analysis with monoclonal antibodies of T-lymphocyte subsets and interleukin-2 oral administration of OK-432 (Picibanil)].
Izumi M
Nihon Geka Gakkai Zasshi; 1993 Jan; 94(1):27-32. PubMed ID: 8437550
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study on the effect of adjuvant immunochemotherapy using OK-432 and 5-FU in pharyngeal and laryngeal cancers].
Yajin K; Harada Y; Tagashira N; Suzuki M; Hirakawa K; Sera K; Nakata M; Takebayashi S; Okazaki H; Yashiki T
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1921-7. PubMed ID: 3289502
[TBL] [Abstract][Full Text] [Related]
15. [A controlled study of surgical adjuvant chemoimmunotherapy with FT-207 and OK-432 for advanced stomach cancer: the fourth study].
Yamamura Y; Yasue M; Nakazato H; Ota K
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):541-8. PubMed ID: 3923941
[TBL] [Abstract][Full Text] [Related]
16. [Studies on the enhancement of anti-tumor activity in patients with cervical cancer by local administration of OK-432].
Yamada Y; Yamamoto K; Wakita K; Shiraki S; Noda K
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3427-31. PubMed ID: 3789753
[TBL] [Abstract][Full Text] [Related]
17. [A case of advanced gastric cancer responsive to intratumoral OK-432 injection].
Sakai Y; Maeda M; Koyama W; Totsuka S; Sakamoto S; Kanayama M
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1978-80. PubMed ID: 3382244
[TBL] [Abstract][Full Text] [Related]
18. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study on the effect of intratumoral administration of OK-432 on breast cancer--anti-tumor immune response at the site of local injection].
Hosokawa T
Nihon Geka Gakkai Zasshi; 1991 May; 92(5):577-86. PubMed ID: 1831533
[TBL] [Abstract][Full Text] [Related]
20. [Clinical investigation of intratumoral OK-432 administration].
Shimada K; Tabuse K; Kono N; Katsumi M; Yamamoto H; Yamamoto Y; Endo A
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1844-9. PubMed ID: 6882008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
